316 related articles for article (PubMed ID: 23052187)
1. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
3. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
[TBL] [Abstract][Full Text] [Related]
4. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
Eckmann C; Heizmann WR; Leitner E; von Eiff C; Bodmann KF
Chemotherapy; 2011; 57(4):275-84. PubMed ID: 21778715
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
Eckmann C; Heizmann W; Bodmann KF; von Eiff C; Petrik C; Loeschmann PA
Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
10. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
[TBL] [Abstract][Full Text] [Related]
11. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
12. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
15. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
Swoboda S; Ober M; Hainer C; Lichtenstern C; Seiler C; Wendt C; Hoppe-Tichy T; Büchler M; Weigand MA
J Antimicrob Chemother; 2008 Mar; 61(3):729-33. PubMed ID: 18222953
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
